Lixiana-H-C-PSUSA-00010387-201610: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Advanced pharmaceutical formulation for targeted therapeutic intervention.
Source
European Medicines Agency
Additional Information
medication.label.product_type
scientific-conclusion
medication.label.permit_number
EMA/373380/2017
medication.label.permit_validity
First published: 2017-07-20T02:00:00Z
Documents
Related Medications
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
Generic Class
AI Voice
Listen to the article content live